Why aren’t digital pills taking off?
While ingestible sensors offer a chance to improve adherence, their use in vulnerable populations remains rife with challenges.
By
Features (web)
Latest in
Features (web)
No drugs for prions: could new approaches alleviate therapeutic scarcity?
An incomplete understanding of the disease, low incidence, and a rapid progression hamper the development of therapies for TSEs.
By
Tapping into pharma’s growing opportunities in digital health
Gérard Klop and Marcos Gallego Llorente of Vintura, explore how companies can grow their sphere of influence in the healthcare…
Magazine: Genomic projects exploit scale as clinical applications play catch-up
In this issue, we take a look at the potential clinical impact of genomic projects, how clinical trials can better…
By
Do generics producers have what it takes to tackle complex and specialty drugs?
Complex and specialty generics offer high rewards, but their development also comes with operational risks.
By
CMO Moves: Regulatory catalysts for drug manufacturing-July
Pharmaceutical Technology does a roundup of regulatory decisions from late April to early May that impact drugs and the CMOs…
By
Neglected tropical diseases: non-profits lead the way as private sectors lags
The Covid-19 pandemic has put extra pressure on research for neglected tropical diseases, but developments continue.
By
The opioid epidemic: is pharma doing enough to develop treatments for the crisis?
Even with academic collaborations, private players are lagging behind public institutions in finding new treatments for opioid addiction.
By